<a href="https://laohu8.com/S/WGRX">Wellgistics Health Inc.</a> posts third quarter net loss of $33.9 million
Wellgistics Health Inc. reported a net operating loss of $33.9 million for the third quarter of 2025, compared to a net operating loss of $1.9 million for the same period in 2024. Net loss per share was $0.46 on 74.4 million weighted average shares outstanding, up from a net loss of $0.04 per share on 48.4 million weighted average shares outstanding in the third quarter of 2024. The increase in net loss was primarily attributed to higher stock-based compensation. During the period, the company focused its sales efforts on the launch of Brenzavvy for the Type 2 diabetes market and prepared for the rollout of its EinsteinRx AI pharmacy hub software. Wellgistics Health also pursued the proposed acquisition of Kare Hub Rx to enhance telepharmacy integration capabilities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1105052) on November 20, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。